Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 161

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 161
---
 a $3.0 million non-dilutive grant from
the National Cancer Institute, part of the National Institutes of Health, is expected to read out in the first half of 2025.

| 82 |

Tolimidone.
Tolimidone was originally discovered by Pfizer Inc., or Pfizer, and was developed through Phase 2 for the treatment of gastric ulcers.
Pfizer undertook a broad pre-clinical program to characterize the pharmacology, pharmacokinetics, metabolism and toxicology of tolimidone.
Pfizer discontinued development of the drug due to lack of efficacy for that indication in Phase 2. Tolimidone is a selective activator
of the enzyme Lyn kinase which increases phosphorylation of insulin substrate -1, thereby amplifying the signaling cascade initiated by
the binding of insulin to its receptor.

We
intend to develop tolimidone for the treatment of T1D. As a lyn kinase activator, tolimidone has been shown in preclinical experiments
to have a role in beta cell survival and proliferation. If replicated in clinical studies, tolimidone could have the potential to be disease
modifying and change the treatment paradigm for T1D. T1D affects approximately 8.4 million people worldwide and there are approximately
500,000 new diagnoses per annum.

As
a first step in the planned continued clinical development of tolimidone, we intend to initiate a Phase 2a dose confirmation study to
establish the optimum dose of tolimidone in patients with T1D. The Phase 2a study will be open-label in approximately 15 patients with
T1D treated over a period of three months with endpoints of change in C-peptide levels, HbA1c and number of hyperglycemic events.

For
additional information regarding tolimidone, see “—Recent Developments—Tolimidone Developments”.

MTX110. Using
our MidaSolve technology in combination with panobinostat, an otherwise insoluble drug and one that we believe is among the most effective
agents, MTX110 is designed for direct-to-tumor treatment of intractable brain cancers. Panobinostat is currently marketed under the brand
Farydak® which is used orally in combination therapy for the treatment of multiple myeloma. We are currently researching the utility
of MTX110 to proof-of-concept stage in three indications:

Glioblast